Showing results (481-490 of 848) with videos related to
Sort By:
Pageof 85
Breathe (Sheffield, England)|August 28, 2024
Stage I and II nonsmall cell lung cancer treatment optionsGeorgia Hardavella, Dimitrios E Magouliotis, Roberto Chalela, et al.Rheumatology (Oxford, England)|April 16, 2026
Transcriptomic profiling of secukinumab-treated psoriatic arthritis reveals potential novel response-associated pathwaysNahdia Afiifah Abdul Jalil, Hector Chinoy, Meghna Jani, et al.Medicine and Science in Sports and Exercise|January 26, 2022
Shoulder Pain, Function, and Ultrasound-Determined Structure in Elite Wheelchair-Using Para Athletes: An Observational StudyCheri A Blauwet, Julian Chakraverty, Wayne Derman, et al.Annals of the Rheumatic Diseases|August 14, 2009
Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritisAnne Hinks, Steve Eyre, Xiayi Ke, et al.Journal of Clinical Microbiology|January 7, 2005
Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patientsFabrizio Fabrizi, Giovanna Lunghi, Filippo Aucella, et al.Acta Oto-Laryngologica|November 2, 2004
Effect of aminoglycoside otic drops on isolated cochlear outer hair cells with and without liver extract activationDukjoo Choi, Seong Kook Park, Paul Martin, et al.The International Journal of Angiology : Official Publication of the International College of Angiology, Inc|August 12, 2024
Are Hospital Admissions (Costs) and Mortality Rate Impacted by Guideline-driven Treatment of Heart Failure?: A Comparison between Participants in the "CorBene" CMP and Standard-care Patients on the Basis of Propensity Score MatchingJosef Ehling, Hans Jürgen Noblé, Detlef Gysan, et al.The American Journal of Gastroenterology|September 14, 2006
Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysisFasiha Kanwal, Mary Farid, Paul Martin, et al.Clinical Therapeutics|October 31, 2015
Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical StudiesPaul Martin, Michael Gillen, David Millson, et al.Clinical Pharmacology in Drug Development|May 11, 2016
Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical StudiesPaul Martin, Michael Gillen, David Millson, et al.Pageof 85